We report the results from the first international multicenter external quality assessment (EQA) studies for molecular and serological typing of group B streptococcus (GBS) strains as part of DEVANI (Design of a Vaccine against Neonatal Infections), a pan-European program. A questionnaire-based surveillance was undertaken among eight laboratories participating in DEVANI and six laboratories not participating in DEVANI from 13 countries in order to assess their current microbiological procedures for GBS screening, diagnosis, and typing. GBS strains from three EQA distributions were characterized using molecular and serological methods based on GBS capsular polysaccharide typing. Participants were asked to test the first distribution using their current serotyping and genotyping methods. The Strep-B-Latex agglutination method was the most widely used method, with a typeability value of >90%. A multiplex PCR assay for GBS capsular gene typing was also used by 2 of 14 centers, which achieved a typeability value of 93%; this assay detected only 9 of 10 GBS capsular polysaccharide genes. From the second and third EQA studies, standardized protocols were prepared for serological and molecular typing of GBS strains based on the Strep-B-Latex agglutination method and a novel multiplex PCR assay that detected all 10 GBS capsular types (Ia to IX). These standardized protocols are being used by many European laboratories, and as the use of these methods increases, it is imperative to continuously improve and assess laboratory performance and offer training to any laboratories that have technical difficulties.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122801 | PMC |
http://dx.doi.org/10.1128/JCM.02365-10 | DOI Listing |
Epidemiol Infect
January 2025
Department of Obstetrics and Gynecology, Juntendo University Urayasu Hospital, Chiba, Japan.
J Infect Dis
December 2024
Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.
Background: Group B Streptococcus (GBS) is a leading cause of neonatal meningitis and sepsis and an important cause of disease in adults. Capsular polysaccharide and protein-based GBS vaccines are currently under development.
Methods: Through national laboratory-based surveillance, invasive GBS isolates were collected from patients of all ages between 2019 and 2020.
J Infect Dis
December 2024
Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, United Kingdom.
Background: Significant disparities in Group B Streptococcus (GBS) colonisation and neonatal disease rates have been documented across different geographical regions. For example, Bangladesh reports notably lower rates compared to the United Kingdom (UK) and Malawi. This study investigates whether this epidemiological variability correlates with the immune response to GBS in these regions.
View Article and Find Full Text PDFPol J Microbiol
December 2024
Department of Medical Microbiology, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria.
group B , GBS) is an important human and animal pathogen. In recent years, the number of streptococcal isolates resistant to antimicrobial agents has increased in many parts of the world. Various mechanisms of antimicrobial resistance and capsular serotypes of GBS with different geographical distributions can be found.
View Article and Find Full Text PDFEur J Clin Microbiol Infect Dis
February 2025
Department of Medical Laboratory Science and Biotechnology, Fooyin University, 151 Chie-Hsueh Road, Ta-Liao District, Kaohsiung City, 83102, Taiwan, ROC.
Purpose: Group B streptococci (GBS) are Gram-positive bacteria that are a leading cause of neonatal infections. Most invasive isolates are β-hemolytic, and hemolytic activity is critical for GBS virulence. Although nonhemolytic GBS strains are occasionally isolated, they are often thought to be attenuated in virulence.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!